Pharmacokinetic Evaluation and Exploration of Antifungal Activity of Synthesized Pyrazole-Based Compounds

¹ University Mohammed Premier, Faculty of Sciences, Laboratory of Environment and Applied Chemistry (LCAE), Oujda, Morocco.
² Laboratory of Processes, Materials, and Environment (LPME), Faculty of Science and Technology, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
³ Multidisciplinary Faculty of Nador, Laboratory of Molecular Chemistry, Materials and Environment (LMCME), University Mohammed Premier, Oujda 60000, Morocco.
⁴ Plant protection laboratory National institute of Agronomic research, CRRA Oujda, 10 Bd MohamedVI, B.P.428, 60000 Oujda, Morocco.

^* For Corresponding author: Email address: This email address is being protected from spambots. You need JavaScript enabled to view it. (O. Riouchi)

Abstract

The synthesized pyrazole-based compounds were evaluated for their pharmacokinetic properties and antifungal activity. The pharmacokinetic results, obtained through the pKCSM server, showed favorable solubility, human intestinal absorption (HIA) greater than 70%, and good permeability to the central nervous system (CNS) for certain compounds, with low inhibition of CYP450 enzymes and predicted toxicity within safe limits. Regarding antifungal activity, the compounds demonstrated effective inhibition of the growth of two pathogenic fungi, with minimum inhibitory concentrations (MIC) ranging from 2 to 16 µg/mL. These results suggest that these compounds possess an optimal pharmacokinetic profile and promising antifungal activity, making them attractive candidates for clinical development. Thus, this study identifies compounds with high therapeutic potential for the treatment of fungal infections while ensuring a good safety profile for future development.